{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:11:51Z","timestamp":1793797911327,"version":"4.6.1"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010822","name":"Science and Technology Bureau of Chengdu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.biopha.2022.113978","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T06:45:45Z","timestamp":1669013145000},"page":"113978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Peptide mediated therapy in fibrosis: Mechanisms, advances and prospects"],"prefix":"10.1016","volume":"157","author":[{"given":"Xun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2022.113978_bib1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"issue":"7835","key":"10.1016\/j.biopha.2022.113978_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03008207.2019.1554755","article-title":"Fibrosis in distinct tissues","volume":"60","author":"Fertala","year":"2019","journal-title":"Connect. Tissue Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib5","first-page":"96","article-title":"Fibrosis--a common pathway to organ injury and failure","volume":"373","author":"Rockey","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5152\/tjg.2018.17330","article-title":"Liver fibrosis","volume":"29","author":"Ayd\u0131n","year":"2018","journal-title":"Turk. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","article-title":"Immune mechanisms in pulmonary fibrosis","volume":"55","author":"Kolahian","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2022.113978_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/978-981-13-8871-2_31","article-title":"New therapies for the treatment of renal fibrosis","volume":"1165","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113978_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis--a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2022.113978_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26154688","article-title":"Downstream Processing of Therapeutic Peptides by Means of Preparative Liquid Chromatography","volume":"26","author":"De Luca","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.113978_bib12","series-title":"Untersuchungen \u00fcber Aminos\u00e4uren, Polypeptide und Prote\u00efne","author":"Deutsch","year":"1899-1906"},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib13","article-title":"Development of Peptide Biopharmaceuticals in Russia","volume":"14","author":"Deigin","year":"2022","journal-title":"NA"},{"issue":"69","key":"10.1016\/j.biopha.2022.113978_bib14","doi-asserted-by":"crossref","first-page":"42457","DOI":"10.1039\/D0RA07204D","article-title":"Pedersen, greening the synthesis of peptide therapeutics: an industrial perspective","volume":"10","author":"Martin","year":"2020","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7","article-title":"Large-scale synthesis of peptides","volume":"55","author":"Andersson","year":"2000","journal-title":"Biopolymers"},{"issue":"5186","key":"10.1016\/j.biopha.2022.113978_bib16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.7973629","article-title":"Synthesis of proteins by native chemical ligation","volume":"266","author":"Dawson","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113978_bib17","first-page":"43","article-title":"Chemoenzymatic synthesis of linear- and head-to-tail cyclic peptides using omniligase-1","volume":"2019","author":"Schmidt","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.7150\/thno.61747","article-title":"Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/0929866523666161222150444","article-title":"Protein and peptide biopharmaceuticals: an overview","volume":"24","author":"Agyei","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.biopha.2022.113978_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2021.11.032","article-title":"Emerging landscape of cell-penetrating peptide-mediated nucleic acid delivery and their utility in imaging, gene-editing, and RNA-sequencing","volume":"341","author":"Geng","year":"2022","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.biopha.2022.113978_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169038","article-title":"Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides","volume":"23","author":"Hao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113978_bib22","first-page":"1","article-title":"Studies of cell-penetrating peptides by biophysical methods","author":"Zorko","year":"2022","journal-title":"Q. Rev. Biophys."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1080\/10717544.2021.1963352","article-title":"In silico identification and experimental validation of cellular uptake and intracellular labeling by a new cell penetrating peptide derived from CDN1","volume":"28","author":"Guo","year":"2021","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.biopha.2022.113978_bib24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/17425247.2018.1517750","article-title":"Mitochondrial-targeted penetrating peptide delivery for cancer therapy","volume":"15","author":"Wu","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2022.113978_bib25","doi-asserted-by":"crossref","first-page":"7269150","DOI":"10.1155\/2020\/7269150","article-title":"The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis","volume":"2020","author":"Tao","year":"2020","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.biopha.2022.113978_bib26","article-title":"Molecular mechanisms and potential new therapeutic drugs for liver fibrosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"44","key":"10.1016\/j.biopha.2022.113978_bib27","doi-asserted-by":"crossref","first-page":"23188","DOI":"10.1074\/jbc.M116.732743","article-title":"Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) Pepducin","volume":"291","author":"Shearer","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"31","key":"10.1016\/j.biopha.2022.113978_bib28","doi-asserted-by":"crossref","first-page":"49075","DOI":"10.18632\/oncotarget.8682","article-title":"Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2022.113978_bib29","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.ymthe.2019.06.017","article-title":"VDAC1-based peptide greatly suppresses steatosis and NASH-associated pathologies in a mouse model","volume":"27","author":"Pittala","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.neo.2018.02.012","article-title":"Targeting liver cancer and associated pathologies in mice with a mitochondrial VDAC1-based peptide","volume":"20","author":"Pittala","year":"2018","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/ml300041g","article-title":"Anti-inflammatory Effect of a cell-penetrating peptide targeting the Nrf2\/Keap1 interaction","volume":"3","author":"Steel","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2022.113978_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105765","article-title":"Research progress on the anti-hepatic fibrosis action and mechanism of natural products","volume":"75","author":"Shan","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.apsb.2020.07.004","article-title":"The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis","volume":"11","author":"Yan","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1478-3231.2008.01841.x","article-title":"Endogenous alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A","volume":"29","author":"Kamiyoshi","year":"2009","journal-title":"Liver Int."},{"issue":"5961","key":"10.1016\/j.biopha.2022.113978_bib35","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/308746a0","article-title":"Isolation and characterization of human calcitonin gene-related peptide","volume":"308","author":"Morris","year":"1984","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5582\/ddt.2013.v7.6.248","article-title":"Synthesis of peptides of Carapax Trionycis and their inhibitory effects on TGF-\u03b21-induced hepatic stellate cells","volume":"7","author":"Hu","year":"2013","journal-title":"Drug Disco Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jphs.2018.01.003","article-title":"Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing NF-kappaB signaling and Wnt\/beta-catenin signaling","volume":"136","author":"Sun","year":"2018","journal-title":"J. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0168-8278(03)00377-5","article-title":"A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo","volume":"39","author":"Kondou","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2022.113978_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lfs.2018.08.031","article-title":"C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis","volume":"209","author":"Bae","year":"2018","journal-title":"Life Sci."},{"issue":"191","key":"10.1016\/j.biopha.2022.113978_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications","author":"Potter","year":"2009","journal-title":"Handb. Exp. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41232-021-00177-4","article-title":"Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice","volume":"41","author":"Nojiri","year":"2021","journal-title":"Inflamm. Regen."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib42","first-page":"331","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"#N. \/A"},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230392","article-title":"High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFR\u03b1-positive bone marrow cells","volume":"15","author":"Goto","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib44","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2022.113978_bib45","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.febslet.2009.05.025","article-title":"Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide","volume":"583","author":"Sonoyama","year":"2009","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.RES.72.5.984","article-title":"Structure, expression, and genomic mapping of the mouse natriuretic peptide type-B gene","volume":"72","author":"Steinhelper","year":"1993","journal-title":"Circ. Res"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib47","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1021\/acs.molpharmaceut.6b01174","article-title":"Highly selective targeting of hepatic stellate cells for liver fibrosis treatment using a d-enantiomeric peptide ligand of Fn14 Identified by MIRROR-IMAGe mRNA Display","volume":"14","author":"Huang","year":"2017","journal-title":"Mol. Pharm."},{"issue":"44","key":"10.1016\/j.biopha.2022.113978_bib48","doi-asserted-by":"crossref","first-page":"31605","DOI":"10.1074\/jbc.274.44.31605","article-title":"Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor","volume":"274","author":"Alberdi","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095443","article-title":"Pigment epithelium-derived factor 34-mer peptide prevents liver fibrosis and hepatic stellate cell activation through down-regulation of the PDGF receptor","volume":"9","author":"Tsai","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbrc.2008.10.154","article-title":"Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat","volume":"378","author":"Ishigaki","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042107","article-title":"Formyl peptide receptor 2 alleviates hepatic fibrosis in liver cirrhosis by vascular remodeling","volume":"22","author":"Jun","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2022.113978_bib52","doi-asserted-by":"crossref","first-page":"12743","DOI":"10.1074\/jbc.275.17.12743","article-title":"Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor","volume":"275","author":"Beljaars","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib53","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1124\/jpet.107.122481","article-title":"Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats","volume":"322","author":"Du","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib54","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-022-29186-8","article-title":"Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2022.113978_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib56","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI116800","article-title":"Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide","volume":"92","author":"Wei","year":"1993","journal-title":"J. Clin. Invest"},{"issue":"2\u20133","key":"10.1016\/j.biopha.2022.113978_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.regpep.2010.06.007","article-title":"Protecting effects of vasonatrin peptide against carbon tetrachloride-induced liver fibrosis","volume":"164","author":"Chen","year":"2010","journal-title":"Regul. Pept."},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib58","first-page":"1049","article-title":"Arg-Gly-Asp (RGD) peptide ameliorates carbon tetrachloride-induced liver fibrosis via inhibition of collagen production and acceleration of collagenase activity","volume":"14","author":"Kotoh","year":"2004","journal-title":"Int. J. Mol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.113978_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/nu9090980","article-title":"1\u03b1,25-dihydroxyvitamin D3 attenuates TGF-\u03b2-induced pro-fibrotic effects in human lung epithelial cells through inhibition of epithelial-mesenchymal transition","volume":"9","author":"Jiang","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2022.113978_bib60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mam.2018.08.004","article-title":"Developmental pathways in the pathogenesis of lung fibrosis","volume":"65","author":"Chanda","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.biopha.2022.113978_bib61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2015.04.012","article-title":"Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions","volume":"97","author":"Della Latta","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1165\/rcmb.2015-0391TR","article-title":"Transforming growth factor-\u03b2: master regulator of the respiratory system in health and disease","volume":"54","author":"Aschner","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0748233709359274","article-title":"A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice","volume":"26","author":"Wang","year":"2010","journal-title":"Toxicol. Ind. Health"},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.etp.2008.04.010","article-title":"synthetic peptide inhibits bleomycin-induced lung fibrosis in mice","volume":"61","author":"2Chen","year":"2009","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2022.113978_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106009","article-title":"Peptide DR8 analogs alleviate pulmonary fibrosis via suppressing TGF-\u03b21 mediated epithelial-mesenchymal transition and ERK1\/2 pathway in vivo and in vitro","volume":"167","author":"Wang","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5\u20136","key":"10.1016\/j.biopha.2022.113978_bib66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/01902148.2019.1614696","article-title":"Peptide PD29 treats bleomycin-induced pulmonary fibrosis by inhibiting the TGF-\u03b2\/smad signaling pathway","volume":"45","author":"Sun","year":"2019","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.biopha.2022.113978_bib67","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fphar.2017.00904","article-title":"GHK peptide inhibits bleomycin-induced pulmonary fibrosis in mice by suppressing TGF\u03b21\/smad-mediated epithelial-to-mesenchymal transition","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib68","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2007.06.004","article-title":"Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library","volume":"39","author":"Dotor","year":"2007","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cyto.2010.11.019","article-title":"Therapeutic effect of a peptide inhibitor of TGF-\u03b2 on pulmonary fibrosis","volume":"53","author":"Arribillaga","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2022.113978_bib70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.taap.2019.05.015","article-title":"M10 peptide attenuates silica-induced pulmonary fibrosis by inhibiting Smad2 phosphorylation","volume":"376","author":"1\\Li","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib71","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.113978_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-016-0335-6","article-title":"C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice","volume":"17","author":"Kimura","year":"2016","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib73","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1039\/C9FO00308H","article-title":"Inhibition of bleomycin-induced pulmonary fibrosis in mice by the novel peptide EZY-1 purified from Eucheuma","volume":"10","author":"Yu","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2022.113978_bib74","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ijbiomac.2019.11.192","article-title":"A novel peptide binding to the C-terminal domain of connective tissue growth factor for the treatment of bleomycin-induced pulmonary fibrosis","volume":"156","author":"Xiao","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-016-0492-7","article-title":"Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice: ANP for pulmonary fibrosis","volume":"18","author":"Okamoto","year":"2017","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib76","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(83)91675-3","article-title":"The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties","volume":"117","author":"Flynn","year":"1983","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.113978_bib77","doi-asserted-by":"crossref","unstructured":"A. Ghebremedhin, A.B. Salam, B. Adu-Addai, S. Noonan, R. Stratton, M.S.U. Ahmed, C. Khantwal, G.R. Martin, H. Lin, C. Andrews, B. Karanam, U. Rudloff, H. Lopez, J. Jaynes, C. Yates, A Novel CD206 Targeting Peptide Inhibits Bleomycin Induced Pulmonary Fibrosis in Mice, bioRxiv (2020).","DOI":"10.1101\/2020.07.27.218115"},{"issue":"136","key":"10.1016\/j.biopha.2022.113978_bib78","doi-asserted-by":"crossref","first-page":"136ra71","DOI":"10.1126\/scitranslmed.3003421","article-title":"A peptide derived from endostatin ameliorates organ fibrosis","volume":"4","author":"Yamaguchi","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2022.113978_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.21037\/atm-21-869","article-title":"Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a)","volume":"9","author":"Liu","year":"2021","journal-title":"Ann. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib81","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.intimp.2015.07.039","article-title":"An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model","volume":"28","author":"Nishimoto","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2022.113978_bib82","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1111\/jcmm.17333","article-title":"FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway","volume":"26","author":"Han","year":"2022","journal-title":"J. Cell. Mol. Med"},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cell.2017.02.031","article-title":"Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging","volume":"169","author":"Baar","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.11.51","article-title":"Rho kinase as a therapeutic target in cardiovascular disease","volume":"7","author":"Surma","year":"2011","journal-title":"Future Cardiol."},{"key":"10.1016\/j.biopha.2022.113978_bib85","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.biopha.2018.08.114","article-title":"Effects of pilose antler peptide on bleomycin-induced pulmonary fibrosis in mice","volume":"109","author":"Zhao","year":"2019","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib86","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-\u03baB in mice","volume":"22","author":"Gou","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113978_bib87","doi-asserted-by":"crossref","DOI":"10.1530\/JME-21-0271","article-title":"C-peptide attenuates hyperglycemia-induced pulmonary fibrosis by inhibiting transglutaminase 2","author":"Jeon","year":"2022","journal-title":"J. Mol. Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113978_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201900129","article-title":"Preventive effects of thermosensitive biopolymer-conjugated C-peptide against high glucose-induced endothelial cell dysfunction","volume":"19","author":"Jung","year":"2019","journal-title":"Macromol. Biosci."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib89","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.110.170977","article-title":"Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity","volume":"335","author":"Pini","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113978_bib90","first-page":"1","article-title":"Pulmonary delivery of a recombinant RAGE antagonist peptide derived from high-mobility group box-1 in a bleomycin-induced pulmonary fibrosis animal model","author":"Piao","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biopha.2022.113978_bib91","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejps.2017.12.019","article-title":"Production and application of HMGB1 derived recombinant RAGE-antagonist peptide for anti-inflammatory therapy in acute lung injury","volume":"114","author":"Lee","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib92","doi-asserted-by":"crossref","first-page":"L1172","DOI":"10.1152\/ajplung.00087.2004","article-title":"C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"287","author":"Murakami","year":"2004","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"522","key":"10.1016\/j.biopha.2022.113978_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat2848","article-title":"Caveolin-1-derived peptide limits development of pulmonary fibrosis","volume":"11","author":"Marudamuthu","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.biopha.2022.113978_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185811","article-title":"R1R2 peptide ameliorates pulmonary fibrosis in mice through fibrocyte migration and differentiation","volume":"12","author":"Chiang","year":"2017","journal-title":"PLoS One"},{"issue":"Pt B","key":"10.1016\/j.biopha.2022.113978_bib95","article-title":"Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells","volume":"101","author":"Duan","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113978_bib96","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18039.1","article-title":"Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system","volume":"8","author":"Iwasaki","year":"2019","journal-title":"F1000Res"},{"issue":"7","key":"10.1016\/j.biopha.2022.113978_bib97","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/01902148.2020.1774823","article-title":"Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis","volume":"46","author":"Yu","year":"2020","journal-title":"Exp. Lung Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diff.2016.05.008","article-title":"The origin of renal fibroblasts\/myofibroblasts and the signals that trigger fibrosis","volume":"92","author":"Sun","year":"2016","journal-title":"Differentiation"},{"key":"10.1016\/j.biopha.2022.113978_bib99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of Renal Fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MNH.0b013e32831c50a1","article-title":"Mechanisms of kidney fibrosis and the role of antifibrotic therapies","volume":"18","author":"Deelman","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib101","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41467-022-28096-z","article-title":"A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-\u03b2 signaling","volume":"13","author":"Yuan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113978_bib102","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2018.03.004","article-title":"The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis","volume":"131","author":"Li","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2022.113978_bib103","first-page":"1864107","article-title":"Glucagon-Like Peptide-1 mediates the protective effect of the dipeptidyl peptidase IV inhibitor on renal fibrosis via reducing the phenotypic conversion of renal microvascular cells in monocrotaline-treated rats","volume":"2018","author":"Xu","year":"2018","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.biopha.2022.113978_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118465","article-title":"Peptide DR8 suppresses epithelial-to-mesenchymal transition via the TGF-\u03b2\/MAPK signaling pathway in renal fibrosis","volume":"261","author":"Deng","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1254\/jphs.FMJ05003X4","article-title":"Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis","volume":"100","author":"Tamada","year":"2006","journal-title":"J. Pharmacol. Sci."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2022.113978_bib106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.regpep.2009.02.006","article-title":"Natriuretic peptide\/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice","volume":"154","author":"Nishikimi","year":"2009","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2022.113978_bib107","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2147\/DDDT.S162288","article-title":"Rapeseed protein-derived antioxidant peptide RAP alleviates renal fibrosis through MAPK\/NF-\u03baB signaling pathways in diabetic nephropathy","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.biopha.2022.113978_bib108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2017.03.037","article-title":"Role of mitochondrial dysfunction in renal fibrosis promoted by hypochlorite-modified albumin in a remnant kidney model and protective effects of antioxidant peptide SS-31","volume":"804","author":"Zhao","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1370","article-title":"Inhibition of renal fibrosis with a human CXCL9-derived glycosaminoglycan-binding peptide","volume":"11","author":"Poosti","year":"2022","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.113.00689","article-title":"Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension","volume":"62","author":"Youn","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.biopha.2022.113978_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131731","article-title":"Immunization with an ApoB-100 Related Peptide Vaccine Attenuates Angiotensin-II Induced Hypertension and Renal Fibrosis in Mice","volume":"10","author":"Honjo","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.biopha.2022.113978_bib112","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.bbadis.2014.09.001","article-title":"A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney ischemia reperfusion injury","volume":"1842","author":"Yang","year":"2014","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.113978_bib113","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12967-015-0699-2","article-title":"Cyclic helix B peptide inhibits ischemia reperfusion-induced renal fibrosis via the PI3K\/Akt\/FoxO3a pathway","volume":"13","author":"Yang","year":"2015","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2022.113978_bib114","doi-asserted-by":"crossref","first-page":"19821","DOI":"10.1038\/srep19821","article-title":"Blocking protein phosphatase 2A signaling prevents endothelial-to-mesenchymal transition and renal fibrosis: a peptide-based drug therapy","volume":"6","author":"Deng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.113978_bib115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","article-title":"Cardiac fibrosis - a short review of causes and therapeutic strategies","volume":"146","author":"Hinderer","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2022.113978_bib116","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12797","article-title":"Prokaryotic expression, purification and evaluation of anti-cardiac fibrosis activity of recombinant TGF-beta latency associated peptide","volume":"10","author":"Song","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.biopha.2022.113978_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175048","article-title":"Suppression of angiotensin II-activated NOX4\/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension","volume":"927","author":"Banks","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113978_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173318","article-title":"Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR\/p70S6K signaling and promoting autophagy","volume":"883","author":"Zheng","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib119","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jfda.2019.11.002","article-title":"Bioactive peptides attenuate cardiac hypertrophy and fibrosis in spontaneously hypertensive rat hearts","volume":"28","author":"Huang","year":"2020","journal-title":"J. Food Drug Anal."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib120","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FJC.0b013e3181b0cf50","article-title":"Long-term carperitide treatment attenuates left ventricular remodeling in rats with heart failure after autoimmune myocarditis","volume":"54","author":"Tanaka","year":"2009","journal-title":"J. Cardiovasc. Pharm."},{"issue":"11 Suppl 1","key":"10.1016\/j.biopha.2022.113978_bib121","first-page":"Ii174","article-title":"Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair","volume":"110","author":"Tsuneyoshi","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2022.113978_bib122","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ndt\/gfr302","article-title":"Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model","volume":"27","author":"Kato","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"issue":"1","key":"10.1016\/j.biopha.2022.113978_bib123","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519897194","article-title":"Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis","volume":"48","author":"Zhao","year":"2020","journal-title":"J. Int. Med. Res"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ejhf.698","article-title":"Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure","volume":"19","author":"Packer","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib125","first-page":"546","article-title":"A human study to evaluate safety, tolerability, and cyclic GMP activating properties of cenderitide in subjects with stable chronic heart failure","volume":"104","author":"Kawakami","year":"2018","journal-title":"#N. \/A"},{"issue":"5225","key":"10.1016\/j.biopha.2022.113978_bib126","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.7543698","article-title":"CFTR as a cAMP-dependent regulator of sodium channels","volume":"269","author":"Stutts","year":"1995","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2022.113978_bib127","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/cbic.202000816","article-title":"The antimicrobial peptide Gad-1 clears pseudomonas aeruginosa biofilms under cystic fibrosis conditions","volume":"22","author":"Portelinha","year":"2021","journal-title":"ChemBioChem"},{"issue":"5","key":"10.1016\/j.biopha.2022.113978_bib128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/bjc.2015.440","article-title":"Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial","volume":"114","author":"Tebbutt","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2022.113978_bib129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biopha.2017.01.039","article-title":"Blocking TGF-\u03b21 by P17 peptides attenuates gastric cancer cell induced peritoneal fibrosis and prevents peritoneal dissemination in vitro and in vivo","volume":"88","author":"Lv","year":"2017","journal-title":"Biomed. Pharm."},{"issue":"44","key":"10.1016\/j.biopha.2022.113978_bib130","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/CJI.0000000000000305","article-title":"Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy","volume":"43","author":"Oyama","year":"2020","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2022.113978_bib132","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.0022-202X.2005.23859.x","article-title":"Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis","volume":"125","author":"Santiago","year":"2005","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113978_bib133","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.biopha.2022.113978_bib134","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3390\/cells10112908","article-title":"Novel peptide therapeutic approaches for cancer treatment","volume":"10","author":"Li","year":"2021","journal-title":"Cells"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:57:02Z","timestamp":1778241422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222013671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":134,"alternative-id":["S0753332222013671"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113978","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide mediated therapy in fibrosis: Mechanisms, advances and prospects","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113978"}}